Featured Research & Clinical Trials Search Results

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT05384535

Prevention
Screening for people at high risk for prostate cancer

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1

Clinicaltrials.gov identifier:
NCT06120491

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 Combined With Hormone Therapy

Clinicaltrials.gov identifier:
NCT05367440

Treatment
Treatment study for metastatic prostate cancer

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Clinicaltrials.gov identifier:
NCT04472338

Prevention
Screening study for people with a mutation linked to prostate cancer risk

New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT06022029

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

Clinicaltrials.gov identifier:
NCT05011383

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

Screening Study for Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Clinicaltrials.gov identifier:
NCT05806515

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Clinicaltrials.gov identifier:
NCT05417594

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Featured Research Search Results